Form 4: Akero Therapeutics Chief Scientific Officer Executes Stock Option and Sells Shares
SEC Form 4 Filing
Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, exercised stock options and sold shares on January 27, 2025, under a pre-arranged trading plan.
Summary
- Timothy Rolph, Chief Scientific Officer of Akero Therapeutics, executed stock options and sold shares on January 27, 2025.
- The transactions were conducted under a Rule 10b5-1 trading plan established on August 12, 2024.
- Rolph exercised options to acquire 14,986 shares at $19.87 and 16,264 shares at $21.10.
- He then sold 13,812 shares at an average price of $54.76, 5,059 shares at an average price of $55.62, and 12,379 shares at an average price of $56.97.
- Following these transactions, Rolph directly owns 170,237 shares of Akero Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document reflects routine insider trading activity under a pre-arranged plan, which is neither positive nor negative for the company's overall prospects.
Industry Context
This is a routine filing for insider transactions and is common for executives who have stock options as part of their compensation. The use of a 10b5-1 plan indicates that the transactions were pre-planned and not based on any material non-public information.
Comparison to Industry Standards
- The use of a Rule 10b5-1 trading plan is a common practice among executives at publicly traded companies, including those in the biotechnology sector like Akero Therapeutics.
- Similar filings are regularly seen from executives at companies such as Madrigal Pharmaceuticals (MDGL) and Viking Therapeutics (VKTX), which are also developing treatments for liver diseases.
- The vesting schedules of the options are typical for executive compensation packages, often with monthly vesting over a period of several years.
Stakeholder Impact
- The transactions may have a minor impact on the stock price due to the sale of shares by a company executive, but the pre-planned nature of the sales should mitigate any significant negative reaction.
Key Dates
| Date | Description |
|---|---|
| 2021-12-08 | Commencement date for vesting of one of the stock option grants. |
| 2023-12-08 | Commencement date for vesting of one of the stock option grants. |
| 2024-08-12 | Date of adoption of the Rule 10b5-1 trading plan. |
| 2025-01-27 | Date of stock option exercise and share sales. |
| 2025-01-29 | Date of filing of the SEC Form 4. |
| 2031-12-07 | Expiration date of one of the stock option grants. |
| 2033-12-08 | Expiration date of one of the stock option grants. |
Keywords
Akero Therapeutics, insider trading, stock options, Rule 10b5-1, Timothy Rolph, share sale, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.